2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid Receptor

Related Products

PDF 1.36 MB

Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol.

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-144827
    AM8936
    		Agonist
    AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC50s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with Ki of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc.
    AM8936
  • HY-110018S
    N-Arachidonyldopamine-d8
    N-Arachidonyldopamine-d8 is the deuterium labeled N-Arachidonyldopamine[1].
    N-Arachidonyldopamine-d<sub>8</sub>
  • HY-P1090A
    Hemopressin(rat) TFA
    		Antagonist
    Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models.
    Hemopressin(rat) TFA
  • HY-120653
    CB1 antagonist 5
    		Antagonist
    CB1 antagonist 5 (Compound 25) is an antagonist for CB1 cannabinoid receptor, with a Ki of 243 nM and an EC50 of 195 nM.
    CB1 antagonist 5
  • HY-110194
    Virodhamine TFA
    		Modulator
    Virodhamine TFA is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine TFA induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine TFA can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases.
    Virodhamine TFA
  • HY-134055
    Arachidonoyl-N,N-dimethyl amide
    Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N,N-dimethyl amide is an analog of anandamide that exhibits weak or no binding to the human central cannabinoid (CB1) receptor (Ki >1 μM). It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.
    Arachidonoyl-N,N-dimethyl amide
  • HY-116661
    Cannabigerovarin
    Cannabigerovarin (CRM) (Item No. 29117) is a certified reference material categorized as a phytocannabinoid.1 This product is intended for research and forensic applications.
    Cannabigerovarin
  • HY-15451R
    MDA 19 (Standard)
    		Agonist
    MDA 19 (Standard) is the analytical standard of MDA 19. This product is intended for research and analytical applications. MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity.
    MDA 19 (Standard)
  • HY-12761R
    A-836339 (Standard)
    		Agonist
    A-836339 (Standard) is the analytical standard of A-836339. This product is intended for research and analytical applications.
    A-836339 (Standard)
  • HY-14137S
    Rimonabant-d10 hydrochloride
    		Antagonist
    Rimonabant-d10 (hydrochloride) is the deuterium labeled Rimonabant hydrochloride. Rimonabant hydrochloride (SR 141716A hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an Ki of 1.8 nM. Rimonabant hHydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3)[1][2].
    Rimonabant-d<sub>10</sub> hydrochloride
  • HY-106010
    LBP1
    		Agonist
    LBP1 is an orally active and low brain penetrant CB1 receptor agonist. LBP1 exhibits significant anti-allodynic and anti-hyperalgesic effects in rodent models of neuropathic pain.
    LBP1
  • HY-113421S
    Linoleoyl ethanolamide-d4
    Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide. Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time.
    Linoleoyl ethanolamide-d<sub>4</sub>
  • HY-108067
    SAD448
    		Agonist
    SAD448 is a CB1 and CB2 receptor agonist. SAD448 can lower intraocular pressure (IOP).
    SAD448
  • HY-103329
    b-AEA
    b-AEA (MM22) is a biotinylated endocannabinoid analog with probe activity. b-AEA is able to accumulate intracellularly in a similar manner to the parent compound AEA. b-AEA does not interact with other components of the endocannabinoid system and therefore does not interfere with their function. b-AEA can be used to visualize the accumulation and intracellular distribution of endocannabinoids.
    b-AEA
  • HY-129787
    PF-03550096
    		Agonist
    PF-03550096 is an orally active synthetic cannabinoid (CB) that selectively targets peripheral CB2 receptors with a Ki value of 7.9 nM. PF-03550096 has analgesic activity.
    PF-03550096
  • HY-W783639
    Bzo-poxizid
    Bzo-poxizid is a synthetic cannabinoid that is a psychoactive substance.
    Bzo-poxizid
  • HY-157312
    TM38837
    		Inhibitor
    CB1 antagonist 4 is a inverse agonist of cannabinoid receptor 1 (CB1) with an IC50 of 0.4 nM. CB1 antagonist 4 can reduce body weight, improve plasma inflammatory markers and glucose homeostasis.
    TM38837
  • HY-122153
    VSN-16
    		Agonist
    VSN-16 is a cannabinoid receptor agonist with vasodilatory activity. VSN-16 can be used for the study of multiple sclerosis.
    VSN-16
  • HY-117754
    PSB-SB1202
    		Agonist
    PSB-SB1202 (Compound 21a) is a phenyl coumarin compound. PSB-SB1202 is a CB1/CB2 agonist with EC50 values of 56 and 14 nM, and Ki values of 32 and 49 nM, respectively.
    PSB-SB1202
  • HY-14137R
    Rimonabant Hydrochloride (Standard)
    		Antagonist
    Rimonabant (Hydrochloride) (Standard) is the analytical standard of Rimonabant (Hydrochloride). This product is intended for research and analytical applications. Rimonabant Hydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an Ki of 1.8 nM. Rimonabant Hydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).
    Rimonabant Hydrochloride (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
Cannabinoid Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.